Your browser doesn't support javascript.
loading
Quality of life in the treatment assessment of postmenopausal osteoporosis / 中南大学学报(医学版)
Journal of Central South University(Medical Sciences) ; (12): 299-303, 2005.
Artigo em Chinês | WPRIM | ID: wpr-813377
ABSTRACT
OBJECTIVE@#To evaluate quality of life (QOL) in the treatment assessment of postmenopausal osteoporosis (PMOP) by comparing the QOL of three treatments hormone replacement treatment, supplement of calcium and vitamin D and risedronate.@*METHODS@#All patients with postmenopausal osteoporosis (PMOP) in this clinical trial had been allocated into 4 groups placebo therapy group, vitamin D addition calcium therapy group, hormone replacement treatment (HRT) therapy group, and risedronate therapy group. We measured the bone mineral density (BMD) and quality of life sale (QOLS) of patients in three times, before the treatment, 3 months after the treatment,and 12 months after the treatment. The differences of the QOL and BMD at the 4 groups and at different time, the linear correlation of the change of QOL and the change of BMD, were both compared after the measurement.@*RESULTS@#The total score of QOL and the score of disease domain and physical domain of HRT therapy group and risedronate therapy group were higher than the placebo therapy group (F = 17. 335, P <0.001), but vitamin D addition calcium therapy group was not different from that of the placebo therapy group. The score of other three domains had no statistically significant difference among the 4 groups. The score of disease domain of the patients of risedronate therapy group started to increase after 3 months of treatment, and continued to increase after 12 months of treatment. The score of disease domain of the patients of HRT therapy group started to increase only after 12 months of treatment. But the score of disease domain of the patients of vitamin D addition calcium therapy group did not increase after 12 months of treatment. The changes of the score of disease domain had the linar correlation with the changes of BMD, and the correlation coefficient was from 0.608 to 0.827.@*CONCLUSION@#QOL may become one of the indexes of medical treatment outcome assessment system for PMOP.
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Psicologia / Qualidade de Vida / Vitamina D / Absorciometria de Fóton / Terapia de Reposição de Estrogênios / Osteoporose Pós-Menopausa / Seguimentos / Alendronato / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Ensaio Clínico Controlado / Estudo observacional / Estudo prognóstico Limite: Feminino / Humanos Idioma: Chinês Revista: Journal of Central South University(Medical Sciences) Ano de publicação: 2005 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Psicologia / Qualidade de Vida / Vitamina D / Absorciometria de Fóton / Terapia de Reposição de Estrogênios / Osteoporose Pós-Menopausa / Seguimentos / Alendronato / Usos Terapêuticos / Tratamento Farmacológico Tipo de estudo: Ensaio Clínico Controlado / Estudo observacional / Estudo prognóstico Limite: Feminino / Humanos Idioma: Chinês Revista: Journal of Central South University(Medical Sciences) Ano de publicação: 2005 Tipo de documento: Artigo